Katherine Tweden - EnteroMedics Co-Founder and VP of Clinical and Regulatory
Founder
Dr. Katherine S. Tweden, Ph.D., was promoted as Senior Vice President Research of the Company. She was the Vice President Clinical and Regulatory of EnteroMedics Inc., since May 2011. Prior to that Dr. Tweden served as our Vice President of Research and Clinical from September 2008 to May 2011 and our Vice President of Research from January 2003 to September 2008. From November 2002 to January 2003, Dr. Tweden was a consultant to Venturi Group, a medical device incubator company. From January 2003 through August 2004, Dr. Tweden worked for Venturi Development Inc. as a consultant to us. From July 1997 to October 2002, Dr. Tweden held positions including Director of Research and Vice President of Research for HeartStent Corporationrationration. From September 1990 to June 1997, Dr. Tweden held the positions of Senior Research Scientist and Principal Research Scientist at St. Jude Medical, Inc since 2015.
| Age | 53 |
| Tenure | 9 years |
| Phone | 651-634-3003 |
| Web | http://www.enteromedics.com |
EnteroMedics Management Efficiency
The company has return on total asset (ROA) of (48.42) % which means that it has lost $48.42 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (146.32) %, meaning that it created substantial loss on money invested by shareholders. EnteroMedics' management efficiency ratios could be used to measure how well EnteroMedics manages its routine affairs as well as how well it operates its assets and liabilities. EnteroMedics Inc., a medical device company, focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. EnteroMedics (ETRM) is traded on NASDAQ Exchange in USA and employs 37 people.Management Performance
| Return On Equity | -146.32 | |||
| Return On Asset | -48.42 |
EnteroMedics Leadership Team
Elected by the shareholders, the EnteroMedics' board of directors comprises two types of representatives: EnteroMedics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of EnteroMedics. The board's role is to monitor EnteroMedics' management team and ensure that shareholders' interests are well served. EnteroMedics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, EnteroMedics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jon Tremmel, Consultant To The CEO and Director | ||
| Peter Delange, Senior Vice President - Operations and Business Development | ||
| Scott Youngstrom, CFO, Chief Compliance Officer | ||
| Dan Gladney, CEO and President and Director | ||
| Nicholas Teti, Independent Director | ||
| Carl Goldfischer, Independent Director | ||
| Catherine Friedman, Independent Director | ||
| Michael Mashaal, Director | ||
| Lori McDougal, Director | ||
| Gary Blackford, Director | ||
| Nick Ansari, Senior Vice President - Sales | ||
| Scott Shikora, Executive Vice President - Medical Affairs and Chief Medical Officer | ||
| Anthony Jansz, Director | ||
| Adrianus Donders, Sr. VP of Research and Advanced Devel. | ||
| Katherine Tweden, Co-Founder and VP of Clinical and Regulatory | ||
| Mark Knudson, Founder and Executive Chairman | ||
| Gregory Lea, CFO, Principal Accounting Officer, Chief Compliance Officer and Secretary | ||
| Paul Hickey, Senior Vice President - Marketing and Reimbursement | ||
| Bobby Griffin, Independent Director | ||
| Tonya Dowd, Vice President - Reimbursement | ||
| Naqeeb Ansari, Senior Vice President - Sales |
EnteroMedics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is EnteroMedics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -146.32 | |||
| Return On Asset | -48.42 | |||
| Current Valuation | 5.39 M | |||
| Shares Outstanding | 14.57 M | |||
| Shares Owned By Insiders | 6.79 % | |||
| Shares Owned By Institutions | 2.64 % | |||
| Number Of Shares Shorted | 1.13 M | |||
| Price To Earning | (0.32) X | |||
| Price To Book | 0.45 X | |||
| Price To Sales | 52.22 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards EnteroMedics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, EnteroMedics' short interest history, or implied volatility extrapolated from EnteroMedics options trading.
Pair Trading with EnteroMedics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if EnteroMedics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in EnteroMedics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Abbott Laboratories could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Abbott Laboratories when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Abbott Laboratories - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Abbott Laboratories to buy it.
The correlation of Abbott Laboratories is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Abbott Laboratories moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Abbott Laboratories moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Abbott Laboratories can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Other Consideration for investing in EnteroMedics Stock
If you are still planning to invest in EnteroMedics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the EnteroMedics' history and understand the potential risks before investing.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |